title: Transforming growth factor-alpha promotes tumor markers secretion from human ovarian cancers in vitro.
abstract: BACKGROUND
  The regulatory mechanism of tumor markers secretion has not been well clarified.
  
  
  METHODS
  Serum levels of CA 125 and tissue polypeptide antigen (TPA) from 17 patients with Stage III serous cystadenocarcinoma were measured prior to an initial surgical treatment. Epidermal growth factor receptor (EGFR) status was examined by an 125I-EGF binding assay in a human serous cystadenocarcinoma cell (SHIN-3) and in the 17 primary carcinomas. SHIN-3 cell and the EGFR-expressing primary cancer cells (n = 4) were cultured with or without various concentrations of transforming growth factor (TGF-alpha), a ligand for EGFR, and the CA 125 and TPA concentrations in the conditioned media were measured.
  
  
  RESULTS
  EGFR was expressed in 12 primary carcinomas and in the SHIN-3 cell, and it was absent in the remaining 5 carcinomas. Pre-therapeutic serum CA 125 and TPA levels were significantly greater (P < 0.05) in patients with EGFR-expressing carcinomas (n = 5). These data suggest a possible involvement of EGFR in regulating these tumor markers secretion. TGF-alpha increased the CA 125 and TPA secretion from SHIN-3 cell. It also promoted the CA 125 secretion in 2 of 4 EGFR-expressing primary ovarian carcinoma specimens.
  
  
  CONCLUSIONS
  These results suggest that a signal through the EGFR may be involved in regulating the CA 125 and TPA secretion from human ovarian carcinomas.
authors.affiliation: Department of Obstetrics and Gynecology, Osaka University Medical School, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Kurachi
authors.forename: H
authors.initials: H
authors.lastname: Adachi
authors.forename: K
authors.initials: K
authors.lastname: Morishige
authors.forename: K
authors.initials: K
authors.lastname: Adachi
authors.forename: T
authors.initials: T
authors.lastname: Takeda
authors.forename: H
authors.initials: H
authors.lastname: Homma
authors.forename: T
authors.initials: T
authors.lastname: Yamamoto
authors.forename: A
authors.initials: A
authors.lastname: Miyake
mesh_terms: D001665:Binding Sites; D014408:Biomarkers, Tumor / Q000378:metabolism*; D018394:CA-125 Antigen / Q000097:blood*; D003536:Cystadenocarcinoma / Q000473:pathology / Q000503:physiopathology*; D066246:ErbB Receptors / Q000032:analysis; D005260:Female; D006801:Humans; D066298:In Vitro Techniques; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000473:pathology / Q000503:physiopathology*; D010455:Peptides / Q000097:blood*; D019396:Tissue Polypeptide Antigen; D016211:Transforming Growth Factor alpha / Q000502:physiology*; D014407:Tumor Cells, Cultured
chemical_list: D014408:Biomarkers, Tumor; D018394:CA-125 Antigen; D010455:Peptides; D019396:Tissue Polypeptide Antigen; D016211:Transforming Growth Factor alpha; D066246:ErbB Receptors